Noguchi K, Sakanashi M
Br J Pharmacol. 1987 Jun;91(2):411-9. doi: 10.1111/j.1476-5381.1987.tb10296.x.
Effects of nipradilol which is a new beta-adrenoceptor blocking agent endowed with nitroglycerin-like vasodilator actions, its denitrated derivative (denitro nipradilol) and propranolol on abnormalities of regional myocardial shortening produced by partial occlusion of the left circumflex coronary artery (LCX) were studied in anaesthetized open-chest dogs. In the presence of LCX stenosis, nipradilol (0.1 mg kg-1, i.v.) produced marked decreases in heart rate and LVdP/dt without a significant increase in left ventricular end-diastolic pressure (LVEDP). It improved impaired myocardial segment shortening and restored normal cardiac lactate metabolism. Denitro nipradilol (0.2 mg kg-1 i.v.) and propranolol (0.2 mg kg-1 i.v.) both caused similar haemodynamic changes to nipradilol but also produced a significant increase in LVEDP. However, improvement by these two agents of regional dysfunction in the ischaemic myocardium was comparable to those seen with nipradilol. All three agents markedly inhibited isoprenaline-induced tachycardia, but vehicle did not. Atrial pacing abolished the beneficial effect of nipradilol on myocardial shortening in the ischaemic region without affecting other haemodynamic parameters. These results indicate that nipradilol alleviates acute myocardial ischaemia produced by coronary stenosis with similar efficacy to denitro nipradilol and propranolol suggesting, that a major part of the beneficial effect of nipradilol may be attributable to its beta-adrenoceptor blocking action.
在麻醉开胸犬身上,研究了新型β-肾上腺素受体阻滞剂尼普地洛(具有类似硝酸甘油的血管舒张作用)、其去硝基衍生物(去硝基尼普地洛)和普萘洛尔对左旋冠状动脉(LCX)部分闭塞所致局部心肌缩短异常的影响。在存在LCX狭窄的情况下,尼普地洛(0.1mg/kg,静脉注射)可使心率和左心室dp/dt显著降低,而左心室舒张末期压力(LVEDP)无明显升高。它改善了受损心肌节段的缩短,并恢复了正常的心脏乳酸代谢。去硝基尼普地洛(0.2mg/kg,静脉注射)和普萘洛尔(0.2mg/kg,静脉注射)引起的血流动力学变化与尼普地洛相似,但也使LVEDP显著升高。然而,这两种药物对缺血心肌局部功能障碍的改善与尼普地洛相当。这三种药物均显著抑制异丙肾上腺素诱发的心动过速,但溶剂对照组则无此作用。心房起搏消除了尼普地洛对缺血区域心肌缩短的有益作用,而不影响其他血流动力学参数。这些结果表明,尼普地洛减轻冠状动脉狭窄所致急性心肌缺血的效果与去硝基尼普地洛和普萘洛尔相似,提示尼普地洛有益作用的主要部分可能归因于其β-肾上腺素受体阻断作用。